



## Genprex to Present at Upcoming Investor and Industry Conferences

October 1, 2018

AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 1, 2018-- **Genprex, Inc. (NASDAQ: GNPX)**, a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that the management team will present at the following upcoming investor and industry conferences:

**Event:** The MicroCap Conference

**Date:** October 2, 2018

**Time:** 12:00 PM EDT

**Location:** New York, NY

**Presenter:** Rodney Varner, Chairman and CEO

**Event:** BIO Investor Forum

**Date:** October 18, 2018

**Time:** 9:30 AM PDT

**Location:** San Francisco, CA

**Presenter:** Dr. Julien Pham, President and COO

### **About Genprex™, Inc.**

Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex's initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex's platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

For more information, please visit [www.genprex.com](http://www.genprex.com) or [www.facebook.com/genprexinc](https://www.facebook.com/genprexinc).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20181001005321/en/>

Source: Genprex, Inc.

Media:

James Heins

ICR Healthcare

203-682-8251

[James.Heins@icrinc.com](mailto:James.Heins@icrinc.com)

or

Investors:

Stephanie Carrington

ICR Healthcare

646-277-1282

[Stephanie.Carrington@icrinc.com](mailto:Stephanie.Carrington@icrinc.com)